https://www.selleckchem.com/pr....oducts/mepazine-hydr
Anaplastic thyroid carcinoma (ATC) is a highly aggressive, undifferentiated rare tumor. Median overall survival is usually between 8 and10 months, with a 1-year survival rate of 20%. Conventional anthracycline based chemotherapy regimens demonstrate low response rates with short duration. Novel therapeutic agents including BRAF and MEK inhibitors based on the molecular landscape of ATC have been investigated. We herein report the rechallenge of a 52-year-old ATC patient with BRAF V600E mutation with dabrafenib plus tramet
처럼
논평
공유하다
